The NIA AD/ADRD Collaboratory will provide the national infrastructure necessary to catalyze and support embedded pragmatic clinical trials of non-pharmacological interventions for persons with dementia. By convening national experts to provide consultation and guidance to Collaboratory-funded pilot projects and NIA-funded trials, the Collaboratory has the potential to transform care delivery, quality, and outcomes for millions of Americans suffering with AD/ADRD. 

To study disparities in health outcomes related to vascular contributions to cognitive impairment and dementia (VCID) in a multicultural rural community, determine rates of impairment, and provide community-based interventions to improve care and reduce costs

To conduct a randomized double-blind, placebo-controlled trial of Lupron and donepezil in women with mild to moderate Alzheimer’s disease to improve cognition and activities of daily living.  

The major goals of D³ include two complementary studies at diverse urban, suburban, and rural primary care practices within Central Indiana and South Florida that will evaluate the predictive performance, the utility and effectiveness of the Passive Digital Marker, the Quick Dementia Rating Scale (QDRS), and the combined approach (Passive + QDRS) in the early detection of Alzheimer’s disease and related dementia (ADRD).